Slingshot members are tracking this event:
U.S. FDA Approval of AJOVY (fremanezumab-vfrm) Injection, Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
AJOVY was evaluated in two Phase III, placebo-controlled clinical trials that enrolled patients with disabling migraine and was studied as both a stand-alone preventive treatment and in combination with oral preventive treatments. In these trials, patients experienced a reduction in monthly migraine days during a 12-week period. The most common adverse reactions (≥5 percent and greater than placebo) were injection site reactions.
Slingshot Insights Explained
Sep 14, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Migraine, Ajovy, Remanezumab-vfrm